Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGEN2373 Monotherapy and Combination with Botensilimab in Advanced Cancer
NCT04121676Phase 1Completed
- Sponsor
- Agenus Inc.
- Start
- Sep 2019
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of AGEN2373 in solid tumor (advanced stage) and melanoma (5 arms), sponsored by Agenus Inc. Primary endpoints: Occurrence of Dose Limiting Toxicity at 21 days and Frequency of treatment-emergent adverse events. Started Sep 2019; status: completed.
02
Drugs
AGEN2373
03
Conditions
solid tumor (advanced stage)melanoma
Beyond the preview
Go deeper on NCT04121676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121676.